

Labiana Joins the IBEX Growth Market 15 as 2026 Traded Value Nearly Triples

Labiana's inclusion takes effect on 21 September after traded value reaches €9.35 million, nearly three times the full-year 2025 figure.

MADRID, SPAIN, September 17, 2026 /EINPresswire.com/ -- [Labiana](#), a Spanish pharmaceutical group specialising in the development, manufacturing and marketing of animal and human health medicines, will join the [IBEX Growth Market 15](#), the index comprising the 15 BME Growth securities with the highest free-float-adjusted market capitalisation among those meeting the liquidity requirements established by BME.



Manuel Ramos, CEO of Labiana

“

Joining the IBEX Growth Market 15 represents a new milestone in Labiana's journey as a listed company and reflects the progress we have made in recent years.”

*Manuel Ramos, CEO of
Labiana*

Labiana's inclusion will take effect on 21 September 2026, with the index adjustment taking place after the close of trading on Friday, 18 September, following the decision adopted by the [Technical Advisory Committee](#) as part of its ordinary review. Alquiber, Biotechnology Assets, Catenon and Indexa Capital will join the index alongside Labiana.

Labiana's inclusion strengthens the representation of healthcare and life sciences in the IBEX Growth Market 15. The company will join the index alongside Biotechnology Assets, while Vytrus Biotech is already a constituent. Retail investor participation is particularly high among the index's

Healthcare-sector securities. According to CNMV data for 2025, retail investors participated in 83.88% of the volume of purchase transactions and 75.26% of the volume of sale transactions involving these securities.

A new milestone supported by growth in trading activity

Labiana's inclusion in the IBEX Growth Market 15 reflects the company's progress in terms of free-float-adjusted market capitalisation and trading activity, as well as its compliance with the liquidity requirements established by BME. This momentum has accelerated particularly during 2026.

The value of Labiana shares traded amounted to €3.30 million in 2025, compared with €2.75 million in 2024. As of 16 September 2026, cumulative traded value had reached €9.35 million, nearly three times the full-year 2025 figure. At that date, the company's market capitalisation exceeded €52 million, compared with €34.95 million at the end of 2025.


"Joining the IBEX Growth Market 15 represents a new milestone in Labiana's journey as a listed company and reflects the progress we have made in recent years, both as a business and in the capital markets. We are confident that our presence in the index will help increase Labiana's visibility and progressively broaden our shareholder base," said Manuel Ramos, CEO of Labiana.

About Labiana

Labiana Health is an independent, integrated international pharmaceutical group specialising in animal and human health. Its business model combines a diversified portfolio of proprietary products with development and manufacturing services for a broad base of pharmaceutical clients.

The Group's products are currently marketed in more than 150 markets, and the company holds registrations for proprietary products in more than 114 countries. Its international presence is supported by two manufacturing plants in Spain operating in accordance with GMP standards, subsidiaries in Turkey, Ecuador and Mexico, a stake in Serbia, a network of multinational clients and licensing agreements with international distributors.

The Group operates through two complementary business lines: CDMO development and manufacturing services for third parties, which provide recurring revenue and visibility, and the development, manufacturing and marketing of proprietary products, which constitutes its main growth driver. Labiana began trading on BME Growth in June 2022, becoming the first Spanish veterinary laboratory to join the market.



Archive image of Labiana's admission to BME Growth in 2022. Source: BME

Cristina Ramos
LABIANA HEALTH, S.A.
+34 634 84 08 24

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/943123383>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.